Foresight Diagnostics

Foresight Diagnostics is excited to share that we have expanded?our strategic partnership with Allogene Therapeutics to support the development of our Foresight CLARITY IUO as an #MRD-based companion diagnostic in the EU, UK, Canada, and Australia. "We are excited about our expanded collaboration with Allogene which will enable development of our MRD assay beyond the U.S.,” said Sandra Close, PhD, Foresight Diagnostics’ Chief Operations and Compliance Officer. “This is an important milestone as we continue to support our biopharma partners implementing MRD-driven clinical trials globally.” Read our press release for more information: https://bit.ly/4iew9zp #MRD #ctDNA

Not only do we champion Allogene Therapeutics' efforts to transform the large B-cell lymphoma treatment landscape beyond the U.S., but this agreement also will enable Foresight Diagnostics to begin to support clinical trials outside of the U.S. as well, including the U.K., Europe, Canada and Australia. ? We're thrilled and grateful for Allogene Therapeutics' continued partnership!

The Foresight Diagnostics team is pleased to welcome Dallas Tester, our new Vice President, Engineering!?? ? At Foresight, Dallas will oversee the development of Foresight’s software and bioinformatics pipelines that produce test results. He will work with Aaron Berlin and the regulatory teams to ensure Foresight’s software and devices are compliant and meet regulatory requirements. Additionally, Dallas will build out data solutions to support lab operations and retrospective analysis. Welcome, Dallas!?

Over the course of cancer treatment, disease burden rapidly declines. But sometimes, residual disease remains at the end of treatment – even if not detected by imaging.? ?? ?? Enter Foresight CLARITY MRD -- a highly sensitive test to detect ultra-low levels of ctDNA present at the end of treatment, which can help guide intervention strategies up to 200 days earlier than imaging-based detection.? ?? Watch this video to see how it can help guide intervention strategies.

While PET scans have been the standard for monitoring patient response to #DLBCL therapy, their accuracy has limitations. Circulating tumor DNA (ctDNA) for minimal residual disease (MRD) detection shows promise as a better tool to more confidently assess response and improve personalized care. Earlier this month, the National Comprehensive Cancer Network? (NCCN?) added ctDNA-MRD testing to their B-cell Lymphoma guidelines to help evaluate PET-positive results after first-line DLBCL therapy. At the Advancing Precision Medicine conference, Mark Roschewski, Clinical Director of the Lymphoid Malignancies Branch at the National Cancer Institute (NCI) Center for Cancer Research, demonstrated how ctDNA testing provides more accurate end-of-therapy assessment than PET scans. Watch a snippet of his presentation. ? Want to learn more and see the study results Dr. Roschewski presented? Watch the entire presentation here: https://lnkd.in/enV_UGa3 #MRD #ctDNA #lymphoma #oncology

Our CEO Jake Chabon presented last week at the J.P. Morgan Healthcare Conference, the largest healthcare investment conference in the industry. PitchBook analysts Kaz Y. Helal, PhD/MBA, and Aaron DeGagne, CFA, share their takeaways from the event in a webinar. They note the exciting progression of innovative diagnostics such as #MRD for cancer, noting that Foresight Diagnostics is among companies leading the way. Catch up on their key JPM themes here https://bit.ly/42mBTCl #JPM25 #HealthcareInvestment #Diagnostics #Cancer

Colorado life sciences companies made news and deepened their connections with investors at this week’s J.P. Morgan Healthcare Conference in San Francisco. Congratulations to presenting companies: Edgewise Therapeutics - President & CEO Kevin Koch, Ph.D. highlighted news of significant milestones in their cardiovascular and muscular dystrophy programs. Umoja Biopharma - CEO Andy Scharenberg, M.D. outlined the company’s continued development of their in vivo CAR T cell therapy pipeline following this week’s $100M Series C fundraising announcement. Foresight Diagnostics - CEO Jake Chabon, Ph.D. shared the company’s leadership in #MRD technology to transform cancer care. CBSA also applauds more than 50 Colorado company leaders who pitched their innovative technologies and demonstrated our state’s collaborative spirit. Shown left to right in photos: Julian Kahn, The Good Science Fund; Callie Weiant, CaliberMRI; Ryan Montes, Ph.D., MicroPure Genomics Inc.; Linda S., J.P. Morgan; Victoria Donovan, Clinically Media; Elizabeth ( Izi ) Stoll, Numiera Therapeutics; Jamie Haggard, Green Sun Medical; Elyse Blazevich, Colorado BioScience Association; and Matthew Teter, Colorado BioScience Association. Elyse Blazevich, Colorado BioScience Association and Ryan Crisman, Umoja Biopharma Jake Chabon, Foresight Diagnostics Elyse Blazevich, Colorado BioScience Association and Rhonda Wallen, Ilera Bio Elyse Blazevich, Colorado BioScience Association and Jodi Scott, Hogan Lovells Matt Teter, Colorado BioScience Association and Elyse Blazevich, Colorado BioScience Association at the Cooley LLP Reception #CoBioScience #StrongerTogether #AllIn

This morning, our CEO Jake Chabon presented at #JPM2025. It was great to connect with industry leaders, investors and partners, and share our groundbreaking work on ultra-sensitive minimal residual disease (MRD) detection through our platform, Foresight CLARITY. Learn more about Foresight, including a recap of 2024 and what's on the horizon for 2025: https://hubs.li/Q032KmzB0 #HealthcareInnovation #MRD #LiquidBiopsy #ForesightDiagnostics

Attending the 43rd Annual J.P. Morgan Healthcare Conference? Our CEO Jake Chabon is scheduled to present on Wednesday, January 15, 2025, at 7:30 a.m. PT. Foresight Diagnostics specializes in ultra-sensitive minimal residual disease (MRD) detection through our platform, Foresight CLARITY?. The heightened sensitivity of the test has the potential to improve personalized treatment for cancer such as solid tumor and hematologic malignancies.?? ? We look forward to engaging with industry leaders, investors, and partners at this premier healthcare investment symposium. To schedule a meeting with our team, please contact [email protected]. #JPM2025 #HealthcareInnovation #MRD #LiquidBiopsy #ForesightDiagnostics?

Foresight is thrilled to share that #ctDNA #MRD testing is now included in National Comprehensive Cancer Network? (NCCN?) Guidelines for #DLBCL – a first for this indication. The guidelines now recommend ctDNA-MRD testing to evaluate PET positive results at end of first-line DLBCL therapy.? ? "Until now, management of patients with a positive or equivocal PET scan at the end of therapy has been a challenging issue, particularly when biopsy is not possible. Furthermore, PET scans have a false positive rate, where 50% of positive scans or more are not due to residual lymphoma,” said Dr. Mark Roschewski?from National Cancer Institute (NCI).?“The inclusion of ctDNA testing in the NCCN Guidelines gives us a powerful tool to address both challenges – providing guidance when biopsy isn't possible and helping us more accurately determine which patients truly need additional therapy." This update follows Foresight's submission of clinical recommendations to the NCCN in August 2024 for the inclusion of ctDNA testing in guidelines, utilizing evidence generated by Foresight CLARITY?. Read our press release for more information - https://t.ly/Vwr_W